New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 7, 2013
07:44 EDTAMRNAmarin receives patent allowance related to Vascepa
Amarin announced that the USPTO has published notification of Notice of Allowance for U.S. Patent Application Serial Number 13/614,146. This application includes claims intended to protect the Vascepa indication approved by the FDA based on Amarin's MARINE clinical trial results. A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an application. The issued patent would have a term that expires no earlier than in 2030. After issuance, Amarin plans to list this patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book. The claims in this allowed application cover a method of use relating to Vascepa's MARINE indication. Specifically, the allowed independent claim covers use of icosapent ethyl, or EPA, including Vascepa, in lowering triglycerides through the daily administration of about 2500 mg to about 5000 mg of EPA, independent of DHA content, present in one or more capsules, effective to lower triglycerides in the subject by at least 25% without increasing LDL-C by more than 5%.
News For AMRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 22, 2014
07:35 EDTAMRNCardiometabolic Health Congress to hold annual meeting
Subscribe for More Information
October 16, 2014
08:08 EDTAMRNAmarin sees cash and cash equivalents of $135.4M at September 30
Subscribe for More Information
October 15, 2014
10:23 EDTAMRNAmarin management to meet with Oppenheimer
Meeting to be held on the West Coast on October 22 hosted by Oppenheimer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use